60 Degrees Pharmaceuticals to Release Interim Babesiosis Trial Data Oct. 6

60 Degrees Pharmaceuticals announced it will disclose interim analysis results from its tafenoquine study in severe babesiosis on October 6, 2026. The company will also host a KOL webinar.